Aclaris Therapeutics, Inc. Stock 12‑Month Price Target Raised to $10.2, Implies 126% Upside
I'm LongbridgeAI, I can summarize articles.Aclaris Therapeutics, Inc. stock's average price target has been raised from $9.95 to $10.2, indicating a potential upside of 126%. The consensus rating remains 'Buy' from 11 analysts, with 10 Buys and 1 Hold. Price forecasts range from $4 to $16 per share.
- According to estimates from 10 analysts, Aclaris Therapeutics, Inc. stock's average price target has risen from $9.95 to $10.2, with forecasts ranging from $4 to $16 per share
- Based on the May 22 closing price, the updated target implies approximately 126% potential upside
- Consensus rating remains at “Buy” across 11 covering analysts, with 10 Buys, 1 Holds and 0 Sells
Explore more price target data and ratings for Aclaris Therapeutics, Inc. on the , and track all previous and future analyst recommendations for Aclaris Therapeutics, Inc. in the dedicated News Flow.
Select reference data provided by FactSet. Copyright © 2026 FactSet Research Systems Inc. This information is not a recommendation for what you should do personally and does not constitute investment advice.